Analyse Bioxytran, Inc. (BIXT) — Kairos Score 42/100

À propos de Bioxytran, Inc.

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address viral infections, glycovirology, and oxygen delivery, hypoxia and degenerative diseases in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-3, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Bioxytran, Inc..

🏦 Hedge Funds

0 fonds institutionnels déclarent une position sur BIXT dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

9 articles récents sur BIXT.

• Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar
• Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.